OHSU

Graduate Studies Faculty

« Back to Search List

Arthur A. Vandenbark, Ph.D.

Professor
Admin Unit: OHSU Multiple Sclerosis Center
Phone: 503-273-5113
Lab Phone: 503-494-5646
Fax: 503-494-9537
Office: Hatfield 6D09
Mail Code: VA R&D 31
Programs:
Molecular Microbiology & Immunology
Neuroscience Graduate Program
Neurology
Research Interests:
Activation of encephalitogenic T cells; T cell receptor peptide therapy; recombinant T cell receptor ligands for regulating neuroantigen specific T cells; translational studies in experimental autoimmune encephalomyelitis and multiple sclerosis. » PubMed Listing
Preceptor Rotations
Dr. Vandenbark has not indicated availability for preceptor rotations at this time.
Faculty Mentorship
Dr. Vandenbark has not indicated availability as a mentor at this time.
Profile

Summary of Current Research

Th1 and Th17 cells specific for neuroantigens such as myelin oligodendroglial glycoprotein (MOG), myelin basic protein (MBP) and proteolipid protein (PLP) can induce severe signs of experimental autoimmune encephalomyelitis (EAE) in mice that include ascending paralysis, demyelination and axonal damage.  These T cell specificities are present and may contribute to central nervous system (CNS) damage in subjects with multiple sclerosis (MS).  Our laboratory designed and developed a new class of antigen specific and highly potent minimal recombinant T cell receptor (TCR) ligands (RTL) that can both prevent and reverse clinical and histological signs of EAE after onset of EAE.  RTL constructs are comprised of a single exon that includes covalently linked β1α1 domains of MHC class II (a partial MHC moiety) with an attached antigenic peptide.  RTL are highly stable proteins of ~25kD produced in E. coli.  Upon purification and folding, RTL assume a conformation similar to the distal domains of full-length class II molecules that bind and present antigenic peptides to activate cognate T cells.  RTL1000, comprised of the human MOG-35-55 peptide covalently linked to the MS risk factor, HLA-DR2b (DRB1*1501), is currently being tested in a Phase 1 clinical trial as a novel therapy for MS. 

Although our studies have documented the ability of RTL to deliver inhibitory signals through the TCR of cognate T cells in a peptide-specific manner, new data showing rapid antigen non-specific RTL binding to antigen-presenting cells (APC), including macrophages, dendritic cells (DC) and B cells, strongly suggest alternative tolerogenic pathways. Both mice and humans have readily detectable levels of natural IgM and IgG antibodies specific for RTL that would likely bind to and signal through Fc receptors (FcR) when complexed with injected RTL, and it is possible that this pathway involves inhibitory FcR such as FcγRIIB.  However, B cell knockout mice with EAE can still be fully treated with RTL in the absence of anti-RTL antibodies, indicating that B cells and Ab mediated signaling alone are not sufficient to account for the therapeutic effects of RTL.  RTL binding to APC is not inhibited by Fc-Blocker, suggesting a third pathway that involves RTL binding to unique RTL-specific receptors (RTLR), a possibility that is now well supported by inhibition of passive EAE using RTL-armed APC and the demonstration of high affinity RTLR on splenic APC and candidate RTLR proteins.  These new findings support our general hypothesis that RTL-induced regulation of antigen specific T cells involves at least 3 separate and possibly redundant inhibitory pathways.  RTL binding to FcR or unique RTL receptors has profound implications in that the RTL binding event itself may activate crucial tolerogenic pathways in APC that may ultimately deliver an inhibitory signal to the antigen-specific T cell.  The goals of our research program include: 1) to assess effects of direct RTL ligation of TCR on Ag specific T cells: Early and downstream activation events and kinetics of binding with TCR will be evaluated in MBP-, PLP- and MOG-specific encephalitogenic T cells ligated with free cognate and control RTL. T cells pretreated with RTL prior to activation with APC/peptide will be evaluated for TCR signaling changes, cytokine profiles and ability to transfer EAE into naïve recipient mice; 2) to evaluate TCR signaling after RTL binding to an RTL receptor (RTLR) on APC: RTL treatment of EAE will be evaluated after blocking cell binding with RTL-specific Fab.  Early and downstream T cell activation will be evaluated after ligation of the TCR with cell bound cognate and control RTL.  APC from RTL-treated mice will be evaluated ex vivo for ability to induce specific tolerance in indicator T cells with cognate TCR.  The RTLR will be sequenced and characterized; 3) to demonstrate a role for FcR binding of RTL:Ab complexes in the RTL therapeutic mechanism. 

Our studies will provide unique insights into the mechanisms of RTL therapy for EAE in mice, with implications for similar evaluations in subjects with MS.   

Impact on Clinical Care: MS patients develop clinical signs at about age 30, and require increasing care as their disease progresses and their productivity decreases over the duration of their normal lifespan. There is currently little to offer clinically for the treatment of MS. Thus, if the RTL approach is found to be effective in MS or other autoimmune disease, it has the potential to improve the type and quality of care available to these patients, and over the long term, to reduce the considerable costs of chronic care.

Recent Publications

Education

  • Ph.D., Washington State University, 1973

Previous Positions

Non-Academic Interests